Print

Raptor Pharmaceutical Inc. (RPTP) Completes Enrollment in Phase 2/3 Clinical Trial of RP103 for the Potential Treatment of Huntington's Disease  
6/18/2012 9:45:19 AM

NOVATO, Calif., June 18, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that enrollment is complete in its Phase 2/3 clinical trial of Cysteamine Bitartrate Delayed-release Capsules (RP103) for the potential treatment of Huntington's Disease. The 96-patient, Phase 2/3 clinical trial is being conducted under a collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), with 8 active clinical sites throughout France.
//-->